GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers
Status:
Completed
Trial end date:
2021-08-30
Target enrollment:
Participant gender:
Summary
This study is a Phase 1, double-blind (sponsor-unblinded), randomized, placebo-controlled,
single- and repeat-dose escalation study including a weekly oral dose (MAD) cohort and a
relative bioavailability (RBA) and food effect (FE) cohort to investigate the safety,
tolerability and PK of VH3739937 in healthy participants. This is a three part study. Part 1
and Part 2 is designed to gain information on the safety, tolerability, and pharmacokinetic
(PK) properties of GSK3739937 when administered as powder-in-a-bottle (PiB). Part 3 will
evaluate the RBA of the GSK3739937 PiB and GSK3739937 Tablet and the safety, tolerability and
PK parameters of the tablet formulation when administered under fasting and fed conditions.